Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHammerson Regulatory News (HMSO)

Share Price Information for Hammerson (HMSO)

Share Price is delayed by 15 minutes
Get Live Data
344.20    -2.40 (-0.69%)
Bid:
345.40
Ask:
345.80
Spread: 0.40 (0.116%)
Market Cap: £1.82b
HMSO Live PriceLast checked at - London Stock Exchange

Intraday Hammerson Share Chart

IASB Accounting Interpretation

22 Feb 2023 07:00

RNS Number : 6295Q
Hammerson PLC
22 February 2023
 

Hammerson plc ("Hammerson" or the "Group")

IASB Accounting Interpretation and Impact on 2021 Income

22 February 2023

 

In October 2022, the IASB IFRS interpretations committee finalised an agenda decision in respect of 'Lessor forgiveness of lease payments (IFRS 9 and IFRS 16)'. 

This stipulates that losses which were incurred on granting rent concessions, which for the Group occurred during the Covid-19 pandemic, should be charged to the income statement in the year they are granted.

In its 2021 audited financial statements, the Group's treatment of Covid-related concessions, consistent with certain other companies within the sector, has been to recognise these as lease modifications such that the impact was initially held on the balance sheet and then spread forward into the income statement over the lease term or period to first break. 

The impact to be reflected in the forthcoming 2022 full year results is that 2021 figures have been restated as set out below:

 

 

As originally reported

£m

Changes

£m

Restated

£m

Gross rental income

241.6

8.8

250.4

Adjusted Net rental income

189.8

 (15.4)

 174.4

Adjusted earnings

 

80.9

 (15.4)

 65.5

 

The change of policy will also benefit 2022's adjusted net rental income and adjusted earnings by c.£2m. There are no other material changes to the Group's income, net assets, or cash flows.

The Group's earnings expectation set out in the Q3 trading, operational and rent collection update dated 8 November 2022 remains unchanged with adjusted earnings not expected to be less than £100m.

The Group will present 2021 and 2022 figures on this basis at the forthcoming 2022 full year results on 9 March 2023.

ENDS

For further information contact:

Josh Warren

Director of Strategy, Commercial Finance and Investor Relations

Tel: 020 7887 1053

Natalie Gunson

Communications Director

Tel: 020 7887 4672

The announcement above has also been released on the SENS system of the Johannesburg Stock Exchange and on Euronext Dublin.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCSELFUFEDSEDE
Date   Source Headline
8th Jun 202612:15 pmRNSAdmission to Trading
8th Jun 202611:00 amRNSDirector/PDMR Shareholding
5th Jun 20268:00 amRNSPublication of Final Terms
2nd Jun 20267:00 amRNSSuccessful pricing of 5-year EUR350m bond
29th May 20263:45 pmRNSHolding(s) in Company
26th May 202610:00 amRNSResults of Dividend Reinvestment Plan
22nd May 20264:15 pmRNSDirector/PDMR Shareholding
19th May 20262:00 pmRNSDirector/PDMR Shareholding
15th May 202612:30 pmRNSDirector/PDMR Shareholding
14th May 20263:00 pmRNSDirector/PDMR Shareholding
30th Apr 20264:30 pmRNSTotal Voting Rights
30th Apr 202611:15 amRNSResult of AGM
30th Apr 20267:00 amRNSHammerson CFO to retire
29th Apr 20267:00 amRNSHolding(s) in Company
28th Apr 20263:00 pmRNSDirector/PDMR Shareholding
24th Apr 20261:30 pmRNSEMTN Programme: Publication of Base Prospectus
24th Apr 20267:00 amRNSHolding(s) in Company
23rd Apr 20267:00 amRNSHolding(s) in Company
8th Apr 20264:00 pmRNSDirector/PDMR Shareholding
7th Apr 202612:45 pmRNSTotal Voting Rights and Capital
30th Mar 202610:00 amRNSDirector/PDMR Shareholding
26th Mar 202611:00 amRNSAnnual Report and Notice of Annual General Meeting
19th Mar 20262:00 pmRNSDirector/PDMR Shareholding
17th Mar 202610:00 amRNSDirector/PDMR Shareholding
17th Mar 20269:00 amRNSDividend Currency Conversion Announcement
25th Feb 20267:01 amRNSDividend Declaration
25th Feb 20267:00 amRNSFinal Results
6th Feb 20267:00 amRNSDirectorate change
28th Jan 20269:00 amRNSNotice of Results
20th Jan 20263:30 pmRNSHolding(s) in Company
22nd Dec 202511:30 amRNSDirector/PDMR Shareholding
22nd Dec 20259:30 amRNSDirector/PDMR Shareholding
15th Dec 20253:00 pmRNSDirector/PDMR Shareholding
11th Dec 20252:15 pmRNSTotal Voting Rights
11th Dec 20252:00 pmRNSDirector/PDMR Shareholding
3rd Dec 20257:00 amRNSDirectorate change
21st Nov 20257:00 amRNSAcquisition of The Oracle and Trading Update
13th Nov 20251:45 pmRNSDirector/PDMR Shareholding
31st Oct 20257:45 amRNSResults of Dividend Reinvestment Plan
28th Oct 20251:00 pmRNSDirector/PDMR Shareholding
24th Oct 20254:00 pmRNSDirector/PDMR Shareholding
23rd Oct 202511:00 amRNSDirector/PDMR Shareholding
22nd Oct 20254:30 pmRNSDirector/PDMR Shareholding
21st Oct 202512:00 pmRNSDirector/PDMR Shareholding
16th Oct 20251:00 pmRNSPublication of Final Terms
9th Oct 20257:00 amRNSBond Pricing, Guidance & Operational Update
25th Sep 20254:30 pmRNSHolding(s) in Company
19th Sep 20253:30 pmRNSDirector/PDMR Shareholding
11th Sep 20254:45 pmRNSHolding(s) in Company
9th Sep 20257:00 amRNSAppointment of Rob Wilkinson as CEO

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.